Sifrol (pramipexole) impact on RLS related quality of life: a 12-weeks observational non-interventional study in patients with primary RLS.
Phase of Trial: Phase IV
Latest Information Update: 31 Oct 2013
At a glance
- Drugs Pramipexole (Primary)
- Indications Restless legs syndrome
- Focus Therapeutic Use
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 08 Jul 2009 Actual patient number (2093) added as reported by ClinicalTrials.gov.
- 10 Feb 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 16 Oct 2007 New trial record.